Key Points
Analysts expect $1.89 EPS and $82.20B revenue from CVS.DE.
Heavy debt at 7.25x net debt to EBITDA raises financial concerns.
Net income declined 61.68% year-over-year despite 7.85% revenue growth.
Meyka AI rates CVS.DE as B grade, suggesting neutral hold position.
CVS Health Corporation (CVS.DE) will report first-quarter earnings on May 6, 2026. Analysts expect earnings per share of $1.89 and revenue of $82.20 billion. The healthcare giant operates across three segments: Health Care Benefits, Pharmacy Services, and Retail/LTC. With a market cap of $90.35 billion and 2.19 million employees, CVS.DE remains a major player in U.S. healthcare. The stock currently trades at €70.50, down 0.65% today. Investors will focus on whether the company can deliver on these estimates amid ongoing healthcare industry pressures.
Earnings Estimates and What They Mean
Analysts project CVS.DE will report $1.89 earnings per share and $82.20 billion in revenue for the upcoming quarter. These figures represent expectations for a company managing massive healthcare operations across insurance, pharmacy, and retail segments.
EPS Estimate Analysis
The $1.89 EPS estimate compares against the company’s trailing twelve-month EPS of $1.19. This suggests analysts expect meaningful earnings growth in the upcoming quarter. However, CVS.DE’s recent financial growth shows mixed signals. Net income declined 61.68% year-over-year, while EPS fell 61.75%. This creates uncertainty about whether the company can meet the higher estimate.
Revenue Projection Context
The $82.20 billion revenue estimate reflects CVS.DE’s scale as a healthcare behemoth. The company generated $316.59 in revenue per share trailing twelve months. Recent revenue growth stands at 7.85% year-over-year, showing steady but modest expansion. The pharmacy and insurance segments drive most revenue, with retail contributing smaller amounts.
Historical Performance Signals
CVS.DE’s earnings history shows volatility. The company’s net income declined significantly while operating cash flow grew 16.82%. This disconnect suggests operational challenges despite cash generation. Free cash flow increased 23.41%, indicating the company converts operations into cash effectively despite profitability pressures.
Key Metrics and Financial Health
CVS.DE’s financial position reveals both strengths and concerns heading into earnings. The company maintains substantial scale but faces profitability challenges that investors must monitor closely.
Profitability and Margins
The company’s net profit margin stands at just 0.44%, among the lowest in healthcare. Operating margin is 1.16%, reflecting thin returns on massive revenue. Gross profit margin of 13.77% shows reasonable product pricing power. However, these margins compress significantly when moving down the income statement, indicating high operating costs and debt service expenses.
Debt and Leverage Concerns
CVS.DE carries substantial debt with a debt-to-equity ratio of 1.06. The company’s net debt to EBITDA reaches 7.25 times, indicating heavy leverage. Interest coverage of 1.49 times raises concerns about debt servicing capacity. The company’s debt grew 12.87% year-over-year, outpacing revenue growth. This leverage limits financial flexibility during downturns.
Cash Flow Strength
Operating cash flow per share reached $8.38 trailing twelve months. Free cash flow per share stands at $6.15, providing dividends and debt reduction capacity. The company pays $2.66 per share in dividends, yielding 3.23%. Cash conversion remains solid despite profitability challenges, suggesting underlying business quality.
What Investors Should Watch
Several factors will determine whether CVS.DE meets or misses earnings expectations on May 6. These metrics provide critical insight into operational performance and future direction.
Segment Performance Breakdown
Investors should examine each segment separately. Health Care Benefits segment growth indicates insurance demand and pricing power. Pharmacy Services results show whether the company maintains market share amid competition. Retail/LTC performance reveals consumer health spending trends. Management guidance on each segment will signal confidence in future growth.
Margin Trends and Cost Control
Watch for gross margin stability or improvement. Operating margin expansion would signal better cost management. The company must demonstrate it can grow revenue while controlling expenses. Any margin compression would raise concerns about competitive pressures or input cost inflation affecting profitability.
Debt Reduction Progress
Management commentary on debt paydown matters significantly. With leverage at 7.25 times net debt to EBITDA, reducing debt strengthens the balance sheet. Free cash flow allocation between dividends, debt reduction, and acquisitions reveals capital priorities. Investors want to see debt declining, not growing faster than earnings.
Meyka AI Grade and Analyst Consensus
Meyka AI rates CVS.DE with a grade of B, suggesting a neutral outlook. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating reflects mixed signals in the company’s fundamentals.
Grade Components Explained
The B grade incorporates multiple factors. DCF valuation analysis shows strong buy signals, suggesting the stock trades below intrinsic value. However, return on equity scores poorly at 2 out of 10, indicating weak profitability relative to shareholder capital. Debt metrics score very low at 1 out of 10, reflecting leverage concerns. Price-to-earnings ratio scores 1 out of 10, suggesting the stock appears expensive on earnings multiples.
What B Grade Means for Investors
A B grade suggests holding current positions rather than aggressive buying or selling. The company has fundamental value but faces operational and financial challenges. Earnings results on May 6 could shift this rating if the company demonstrates margin improvement or debt reduction progress. Conversely, disappointing results could trigger a downgrade to C or lower.
Final Thoughts
CVS Health’s May 6 earnings will reveal if the company meets $1.89 EPS and $82.20 billion revenue targets. Despite strong cash generation, thin margins, heavy debt, and declining profitability pose challenges. Investors should monitor segment performance, margin trends, and debt reduction. The B grade reflects solid cash flows offset by leverage concerns and weak equity returns. At €70.50 with a 59.24 P/E ratio, the stock offers limited upside without operational improvement. Management guidance on healthcare reform and competitive positioning in pharmacy and insurance will be critical.
FAQs
What EPS and revenue do analysts expect from CVS.DE earnings?
Analysts expect $1.89 EPS and $82.20 billion revenue. EPS represents growth from trailing $1.19, but recent 61.75% YoY earnings decline creates uncertainty about meeting expectations.
How does CVS.DE’s debt level affect earnings quality?
CVS.DE’s 7.25x net debt-to-EBITDA and 1.06 debt-to-equity ratios raise concerns. Weak 1.49x interest coverage limits financial flexibility and diverts cash from growth, pressuring long-term earnings quality.
Will CVS.DE beat or miss earnings estimates?
Mixed signals complicate prediction. 7.85% revenue growth supports the $82.20B estimate, but 61.68% net income decline suggests $1.89 EPS may be optimistic. Management cost control execution will determine results.
What does Meyka AI’s B grade mean for CVS.DE investors?
The B grade suggests neutral hold positioning. DCF undervaluation is offset by weak ROE and high debt concerns. Rating reflects solid cash flows balanced against operational challenges; earnings results could shift the grade.
What should investors watch during the earnings call?
Monitor segment performance, gross and operating margin trends, and debt reduction progress. Focus on healthcare reform impacts, competitive positioning, and commentary on cost inflation and pricing power.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)